With FDA approval for its atopic dermatitis drug Adbry, LEO Pharma will reach the U.S market ahead of an Eli Lilly atopic dermatitis drug that addresses the same target. LEO will also able to offer patients an alternative to the blockbuster Sanofi/Regeneron Pharmaceuticals drug Dupixent.
Repurpose.AI, a San Diego-based drug discovery startup, struck a partnership with LEO Pharma to identify potential dermatology drug candidates. The startup searches through a library of drugs that have passed Phase I trials, but might not have been commercialized, to find promising candidates.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
LEO Pharma, which has had a primary focus on skin conditions like psoriasis, has launched its new Innovation Lab to further explore treatment options that don't involve medication.
A gel to treat a precancerous skin condition has been approved by the U.S. Food and Drug Administration. Picato gel, produced by LEO Pharma is applied to the skin to treat actinic keratosis, a skin condition caused by overexposure to the sun. The condition produces dry, scaly patches or lesions that form on the outermost […]